Papers/PMID:31745072
High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels.
Translational psychiatry2019The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
all-cis-5,8,11,14,17-icosapentaenoic acid — no detected effect on C-reactive protein concentration
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Changes in hs-CRP and BNDF values are also reported in Table 2; there were no differences between EPA and the placebo (p = 0.747 and p = 0.070, respectively).”
Quoted verbatim from High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels.. - Study
- RCT
- Participants
- 80
- Duration
- 3 months
- Dose
- 1.2 g/day EPA; the form of the EPA is not stated
- Population
- Children and adolescents aged 6 to 18 years with a DSM-5 diagnosis of attention deficit hyperactivity disorder, either drug naive or unmedicated for the previous six months, recruited at one hospital in Taiwan
High-dose eicosapentaenoic acid (EPA) improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder (ADHD) and low endogenous EPA levels.2019PMID:31745072An author is affiliated with a producerPermalink